Literature DB >> 11384657

Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report.

Y Abramov1, M Fatum, D Abrahamov, J G Schenker.   

Abstract

OBJECTIVE: To compare the efficacy and safety of 6% hydroxyethylstarch and human albumin as colloid solutions for treatment of severe ovarian hyperstimulation syndrome (OHSS).
DESIGN: Controlled cohort study.
SETTING: Tertiary medical center. PATIENT(S): Sixteen patients with severe OHSS. INTERVENTION(S): Six percent hydroxyethylstarch (6 patients) and human albumin (10 patients). MAIN OUTCOME MEASURE(S): Urine output, number of abdominal and pleural drainage procedures, complications, duration of hospitalization, and perinatal outcome. RESULT(S): Patients who received 6% hydroxyethylstarch had higher urine output, needed fewer abdominal and pleural paracenteses, and had a shorter hospital stay than those who received human albumin. In each group, no adverse effects or congenital malformations were observed and the rates of miscarriage were similar. CONCLUSION(S): These results suggest that 6% hydroxyethylstarch may be superior to albumin as a colloid solution for the treatment of severe OHSS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384657     DOI: 10.1016/s0015-0282(01)01784-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction.

Authors:  Ataollah Ghahiri; Neda Mogharehabed; Minoo Movahedi; Naeimehossadat Hosseini
Journal:  J Res Med Sci       Date:  2015-07       Impact factor: 1.852

3.  Artificial colloids versus human albumin for the treatment of ovarian hyperstimulation syndrome: A retrospective cohort study.

Authors:  Tetsuji Minami; Hayato Yamana; Mph Ph D; Daisuke Shigemi; Hiroki Matsui Mph; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Int J Reprod Biomed       Date:  2019-11-07

Review 4.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

Review 5.  Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.

Authors:  Bahia Namavar Jahromi; Mohammad Ebrahim Parsanezhad; Zahra Shomali; Pardis Bakhshai; Mahshid Alborzi; Najmeh Moin Vaziri; Zahra Anvar
Journal:  Iran J Med Sci       Date:  2018-05

6.  Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.

Authors:  Jing Zhao; Bin Xu; Xi Huang; Yi Yan; Yanping Li
Journal:  Reprod Health       Date:  2020-11-20       Impact factor: 3.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.